Cargando…

Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial

BACKGROUND: Remission is the primary objective of treating juvenile idiopathic arthritis (JIA). It is still debatable whether early intensive treatment is superior in terms of earlier achievement of remission. The aim of this study was to evaluate the effectiveness of early etanercept+methotrexate (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alexeeva, Ekaterina, Horneff, Gerd, Dvoryakovskaya, Tatyana, Denisova, Rina, Nikishina, Irina, Zholobova, Elena, Malievskiy, Viktor, Santalova, Galina, Stadler, Elena, Balykova, Larisa, Spivakovskiy, Yuriy, Kriulin, Ivan, Alshevskaya, Alina, Moskalev, Andrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788754/ https://www.ncbi.nlm.nih.gov/pubmed/33407590 http://dx.doi.org/10.1186/s12969-020-00488-9

Ejemplares similares

Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data
por: Alexeeva, Ekaterina, et al.
Publicado: (2023)

P02-011 - TRAPS syndrome debuted as systemic JIA
por: Sleptsova, T, et al.
Publicado: (2013)

Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry
por: Armaroli, Giulia, et al.
Publicado: (2020)

Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)
por: Horneff, G, et al.
Publicado: (2008)

DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
por: Vojinovic, J, et al.
Publicado: (2008)

Etanercept therapy in JIA: impact on the need for intra-articular steroid injections
por: Pain, CE, et al.
Publicado: (2008)

DNase I levels and disease outcome in JIA patients treated with etanercept
por: Lazarević, D, et al.
Publicado: (2011)

Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?
por: Cron, Randy Q, et al.
Publicado: (2010)

The use of Etanercept and Adalimumab in the management of JIA: a 5-year follow-up study
por: Trachana, M, et al.
Publicado: (2008)

The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data
por: Davies, Rebecca, et al.
Publicado: (2020)

Evaluation of disease activity in a population of Russian JIA patients
por: Kostareva, OM, et al.
Publicado: (2011)

No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis – a matched pair analysis
por: Schmeling, Heinrike, et al.
Publicado: (2012)

Indirect comparison of etanercept and abatacept efficacy and safety in patients with polyarticular juvenile idiopathic arthritis
por: Loskutova (Konopelko), OU, et al.
Publicado: (2014)

An in-depth analysis of young people's experience of their juvenile idiopathic arthritis (JIA) once receiving Etanercept
por: Livermore, P, et al.
Publicado: (2008)

Inflence of clinical and genetic characteristics on ability to achive and maintain remission in JIA patients on etanercept treatment
por: Lazarevic, Dragana S, et al.
Publicado: (2014)

PReS-FINAL-2062: The need for conducting different rehabilitation complexes for patients with juvenile idiopathic arthritis (JIA)
por: Shelepina, TA, et al.
Publicado: (2013)

Serious infections in JIA patients upon MTX, TFN inhibitors and combinations
por: Horneff, Gerd, et al.
Publicado: (2014)

Treat to Target (Drug-Free) Inactive Disease in JIA: To What Extent Is This Possible?
por: Ramanan, Athimalaipet V., et al.
Publicado: (2022)

Multicentric Castleman's Disease (CD) in juvenile idiopathic arthritis (JIA) treated with etanercept: coincidence or causal relationship?
por: Rossi, L, et al.
Publicado: (2008)

PReS-FINAL-2096: Herpes virus infections in patients with juvenile idiopathic arthritis (JIA) treated with etanercept
por: Nicolai, R, et al.
Publicado: (2013)

Quality of life in patients with juvenile arthritis: adalimumab might make a difference
por: Denisova, Rina, et al.
Publicado: (2011)

Polyarticular juvenile idiopathic arthritis (pJIA): clinical and serologic predictors of inactive disease (ID)
por: Meiorin, Silvia
Publicado: (2014)

PReS-FINAL-2142: Predictors of persistent remission following etanercept (ETN) withdrawal in patients with juvenile idiopathic arthritis (JIA)
por: Perfetti, F, et al.
Publicado: (2013)

Evaluation of the JIA treatment with adalimumab in ukraine
por: Ponochevna, Elena, et al.
Publicado: (2014)

PReS-FINAL-2093: Can clinical response within 12 weeks in JIA-etanercept receivers predict the future clinical remission?
por: Pratsidou-Gertsi, P, et al.
Publicado: (2013)

Inactive disease and remission rates after intraarticular steroids as initial therapy for juvenile idiopathic arhtritis (JIA)
por: Sato, JO, et al.
Publicado: (2011)

Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia
por: Alexeeva, Ekaterina I., et al.
Publicado: (2017)

Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis
por: Alongi, Alessandra, et al.
Publicado: (2022)

Epidemiology of JIA
por: Lahdenne, Pekka
Publicado: (2014)

Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)
por: Foeldvari, Ivan, et al.
Publicado: (2019)

Predictors of Unfavorable Outcomes in Patients with Atrial Fibrillation and Concomitant Heart Failure with Different Ejection Fractions: RIF-CHF Register One-Year Follow-Up
por: Zhirov, Igor, et al.
Publicado: (2019)

Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
por: Klotsche, Jens, et al.
Publicado: (2021)

Correction to: Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)
por: Foeldvari, Ivan, et al.
Publicado: (2020)

Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
por: Thiele, Franz, et al.
Publicado: (2021)

JIA pathogenesis - genetics
por: Thomson, Wendy
Publicado: (2014)

Response to Jia and Wang
por: Liu, Xu, et al.
Publicado: (2020)

PReS-FINAL-2139: Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study
por: De Benedetti, F, et al.
Publicado: (2013)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Structural Analysis of Oxidized Cerebrosides from the Extract of Deep-Sea Sponge Aulosaccus sp.: Occurrence of Amide-Linked Allylically Oxygenated Fatty Acids
por: Santalova, Elena A., et al.
Publicado: (2020)

Efficacy of abatacept in juvenile idiopathic arthritis related uveitis
por: Katargina, LA, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_4arlcr3c6cstaukhcq100t3mv5